Helena Ågerstam

Medicine & Life Sciences

1. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
2. Acute Myeloid Leukemia 70%
3. Receptor, Fibroblast Growth Factor, Type 1 55%
4. Antibodies 49%
5. Myeloid Progenitor Cells 48%
6. Myeloid Cells 45%
7. Gene Fusion 43%
8. Heterografts 36%
9. Oncogene Fusion 34%
10. Protein-Tyrosine Kinases 32%
11. 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 30%
12. Stem Cells 29%
13. ponatinib 27%
14. Fetal Blood 27%
15. nucleophosmin 24%
16. Hematopoietic Stem Cells 24%
17. STAT5 Transcription Factor 24%
18. Interleukin-1 23%
19. Disease Progression 23%
20. Dasatinib 23%
21. Interleukin-1 Receptors 22%
22. Complement Receptors 22%
23. Myeloproliferative Disorders 21%
24. Cytokines 20%
25. Blood Cells 20%
26. B-Lymphoid Precursor Cells 20%
27. Imatinib Mesylate 19%
28. Transcriptome 17%
29. Mast Cells 16%
30. Therapeutics 16%
31. Erythroid Cells 15%
32. Therapeutic Uses 15%
33. Bone Marrow Cells 15%
34. Genes 14%
35. Neoplasms 13%
36. Leukemia 13%
37. Chromosomes, Human, Pair 9 12%
38. Blast Crisis 10%
39. Clone Cells 10%
40. Haploinsufficiency 10%
41. Apoptosis 10%
42. Exons 9%
43. Proteins 9%
44. Cell Differentiation 9%
45. Interleukin-1 Receptor Accessory Protein 8%
46. Transplantation 8%
47. Leukemia, Myeloid, Chronic Phase 7%
48. Chromosomes, Human, Pair 22 7%
49. Cell Proliferation 7%
50. Bone Marrow 6%